NASDAQ: CASI | 中文 | Contact Us

CASI News

CASI Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-CD38 Monoclonal Antibody (MAB) CID-103 In Autoimmune Field

May 24, 2022

ROCKVILLE, MD. and BEIJING, China (May 24, 2022) CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd., (“TIANSHI”) a clinical stage pharmaceutical company organized and existing under the laws of the People’s Republic of China (“PRC”). The Sublicense Agreement grants TIANSHI an exclusive, perpetual, worldwide license for the investigational anti-CD38 monoclonal antibody (Mab), CID-103, in the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in humans.

Read the press release.


CASI Pharmaceuticals Announces First Quarter 2022 Financial Results

May 12, 2022

ROCKVILLE, MD. and BEIJING, China (May 12, 2022) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022.

Read the press release.


U.S. FDA-Approved Product

Evomela®

Multiple Myeloma

Clinical Candidates

CNTC19

Hematological Malignancies

BI-1206

Non-Hodgkin's Lymphoma and Solid Tumors

CB-5339

AML, MDS and Solid Tumors

CID-103

Multiple Myeloma
Learn more about our product pipeline

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More